Collegium Pharma (COLL) Tops Q4 EPS by 9c, provides guidance

Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of $1.75, $0.09 better than the analyst estimate of $1.66. Revenue for the quarter came in at $181.9 million versus the consensus estimate of $179.48 million.

Guidance:

Product Revenues, Net $735.0 to $750.0 million
Adjusted Operating Expenses
(Excluding Stock-Based Compensation) $220.0 to $230.0 million
Adjusted EBITDA
(Excluding Stock-Based Compensation) $435.0 to $450.0 million

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Trinity Capital posts $709M in new commitments for Q2 2026
• Boeing 737 Max 7 nears FAA certification after years of delays - WSJ